A randomized, clinical trial to assess the relative efficacy and tolerability of two doses of etoricoxib versus naproxen in patients with ankylosing spondylitis
暂无分享,去创建一个
P. Peloso | J. Sieper | Z. Popmihajlov | A. Mehta | P. Stryszak | K. Bickham | Eva Balazcs | N. Frontera
[1] E. Akl,et al. American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network 2015 Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis , 2016, Arthritis & rheumatology.
[2] C. Turesson,et al. Mortality in ankylosing spondylitis: results from a nationwide population-based study , 2015, Annals of the rheumatic diseases.
[3] M. Ward,et al. Comparative efficacy of non-steroidal anti-inflammatory drugs in ankylosing spondylitis: a Bayesian network meta-analysis of clinical trials , 2015, Annals of the rheumatic diseases.
[4] U. Syrbe,et al. Effect of continuous versus on-demand treatment of ankylosing spondylitis with diclofenac over 2 years on radiographic progression of the spine: results from a randomised multicentre trial (ENRADAS) , 2015, Annals of the rheumatic diseases.
[5] S. Brophy,et al. Fatigue in ankylosing spondylitis: treatment should focus on pain management. , 2013, Seminars in arthritis and rheumatism.
[6] J. Braun,et al. First update of the current evidence for the management of ankylosing spondylitis with non-pharmacological treatment and non-biologic drugs: a systematic literature review for the ASAS/EULAR management recommendations in ankylosing spondylitis. , 2012, Rheumatology.
[7] E. Märker-Hermann,et al. Effect of non-steroidal anti-inflammatory drugs on radiographic spinal progression in patients with axial spondyloarthritis: results from the German Spondyloarthritis Inception Cohort , 2012, Annals of the rheumatic diseases.
[8] P. Peloso,et al. Longitudinal Numbers-Needed-To-Treat (NNT) for Achieving Various Levels of Analgesic Response and Improvement with Etoricoxib, Naproxen, and Placebo in Ankylosing Spondylitis , 2011, BMC musculoskeletal disorders.
[9] M. Dougados,et al. 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis , 2011, Annals of the rheumatic diseases.
[10] M. Siddiqui,et al. Etoricoxib: a review of its use in the symptomatic treatment of osteoarthritis, rheumatoid arthritis, ankylosing spondylitis and acute gouty arthritis. , 2009, Drugs.
[11] C. Cannon,et al. Cardiovascular safety and gastrointestinal tolerability of etoricoxib vs diclofenac in a randomized controlled clinical trial (The MEDAL study). , 2009, Rheumatology.
[12] C. Cannon,et al. Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison , 2007, The Lancet.
[13] C. Bombardier,et al. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison , 2006, The Lancet.
[14] J. Emberson,et al. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials , 2006, BMJ : British Medical Journal.
[15] B. Collett,et al. Survey of chronic pain in Europe: Prevalence, impact on daily life, and treatment , 2006, European journal of pain.
[16] M. Dougados,et al. ASAS/EULAR recommendations for the management of ankylosing spondylitis , 2005, Annals of the rheumatic diseases.
[17] M. Dougados,et al. Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial. , 2005, Arthritis and rheumatism.
[18] M. Dougados,et al. Evaluation of the efficacy of etoricoxib in ankylosing spondylitis: results of a fifty-two-week, randomized, controlled study. , 2005, Arthritis and rheumatism.
[19] M. Dougados,et al. Efficacy of cyclo-oxygenase-2 inhibition by etoricoxib and naproxen on the axial manifestations of ankylosing spondylitis in the presence of peripheral arthritis , 2005, Annals of the rheumatic diseases.
[20] A. Cats,et al. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. , 1984, Arthritis and rheumatism.
[21] E. L. Persons,et al. Ankylosing Spondylitis , 1955, GP.